Proton pump inhibitors (PPIs) don’t directly cause osteoporosis, but long-term use is linked to a meaningful increase in fracture risk. A meta-analysis of 11 international studies found PPI users had a 30% higher risk of hip fractures and a 56% higher risk of spine fractures compared to non-users. The risk appears to climb with duration and dose, and the FDA has added fracture warnings to both prescription and over-the-counter PPI labels.
That said, the relationship is more nuanced than a simple cause-and-effect. Here’s what the evidence actually shows and what it means for you.
How PPIs Affect Your Bones
PPIs work by shutting down acid pumps in your stomach. That’s great for heartburn and ulcers, but stomach acid plays a key role in absorbing calcium from food. When acid levels drop, your small intestine absorbs less calcium, and over time, that can chip away at bone mineral density.
There’s a second mechanism that may matter even more. The same type of acid pump that PPIs block in your stomach also exists in osteoclasts, the cells responsible for breaking down old bone so new bone can replace it. By interfering with these cells, PPIs could disrupt the normal cycle of bone turnover. When that cycle goes wrong, bones gradually weaken.
PPIs also reduce absorption of magnesium by changing the pH in your intestine, making it harder for magnesium to bind to its transport channel. Low magnesium levels independently contribute to bone loss. Chronic PPI use has also been associated with lower vitamin B12 and iron absorption, and with changes in vitamin D and calcium metabolism, all of which play supporting roles in maintaining bone strength.
How Much the Risk Increases
The numbers from large-scale studies paint a consistent picture. Across 11 studies, PPI users showed a 30% increased risk of hip fracture, a 56% increased risk of spine fracture, and a 16% increased risk of fracture at any site. These are relative increases, not absolute ones, so the actual number of extra fractures depends heavily on your baseline risk. A 30% increase on a very small risk is still a small risk. But for someone already vulnerable to fractures, it becomes more significant.
Duration matters considerably. One large study found no significant association between PPI use and osteoporotic fractures for durations of six years or less. But after seven or more years of use, the risk of an osteoporosis-related fracture nearly doubled (92% increase). Hip fracture risk specifically rose after five or more years, and after seven years, it jumped to more than four times higher than baseline. That’s a steep increase for the longest-term users.
Who Faces the Greatest Risk
Postmenopausal women are the group most studied and most potentially affected. Estrogen helps protect bone density, so after menopause, bone loss accelerates naturally. Adding a PPI on top of that existing vulnerability could compound the problem. Studies in elderly women have found that PPI use, particularly within the past year or for more than a year continuously, was associated with increased fracture risk compared to those using milder acid suppressants.
Older adults in general face higher risk because they tend to use PPIs for longer periods, often have lower baseline calcium intake, and are already losing bone density with age. If you fall into one of these groups and have been on a PPI for years, the risk profile is worth paying attention to.
What the FDA and Medical Groups Say
The FDA issued a safety communication noting that the highest fracture risk was seen in patients taking high-dose prescription PPIs or using them for a year or more. Over-the-counter PPIs are sold at lower doses and intended for only 14 days of use at a time, with no more than three 14-day courses per year. The FDA revised OTC labels to include fracture risk information as a precaution, and advises against using OTC PPIs at higher doses or for longer than directed.
The American Gastroenterological Association (AGA) takes a more measured stance. Their best practice advice states that long-term PPI users should not routinely screen for bone mineral density loss. In other words, being on a PPI alone isn’t reason enough to start getting bone density scans. The AGA’s position reflects the fact that while the statistical association exists, it remains modest for most users and doesn’t warrant blanket monitoring.
H2 Blockers as an Alternative
H2 receptor antagonists (like famotidine) suppress acid through a different, weaker mechanism. When researchers directly compared PPI users to people taking only H2 blockers, PPI use was associated with a 13% higher risk of osteoporotic fractures. H2 blockers themselves have not been significantly linked to fracture risk. Their acid suppression is less potent and the body develops tolerance to them more quickly, which may explain why they don’t carry the same bone-related concerns.
For people with mild acid reflux who don’t strictly need the stronger suppression of a PPI, switching to an H2 blocker could be a reasonable conversation to have with a prescriber, particularly if long-term use is expected.
Protecting Your Bones While on a PPI
The type of calcium you take matters more than you might expect. Calcium carbonate, the most common and cheapest supplement, requires stomach acid to be absorbed. In people with very low stomach acid from PPI use, absorption of calcium carbonate taken on an empty stomach essentially drops to zero. Calcium citrate, on the other hand, dissolves regardless of stomach acid levels and is absorbed normally. One study in postmenopausal women found calcium citrate provided 94% more calcium absorption than calcium carbonate.
If cost makes calcium citrate impractical, taking calcium carbonate with a meal improves its absorption significantly, since food triggers whatever acid production remains. Dairy products like milk and cheese also contain calcium in a form that absorbs well regardless of stomach pH.
Beyond supplementation, the most effective strategy is simply using PPIs at the lowest effective dose for the shortest necessary time. Many people end up on PPIs indefinitely after an initial prescription without ever reassessing whether they still need them. Given that fracture risk climbs steeply after five to seven years of continuous use, periodic re-evaluation of whether you still need the medication is one of the most practical steps you can take.